Merck, 345832-100UG, Galectin-3C, Human, Recombinant, E. coli

General description
Recombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
Physical form
Lyophilized from deionized water, 2µg lactose/µg lectin.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
Other Notes
Hoyer K.K., et al. 2004. Am. J. Pathol.164, 893.
John C.M., et al. 2003. Clin. Cancer Res.9, 2374.
Iurisci, I., et al. 2000. Clin Cancer Res6, 1389.
Van Den Brule, F. A., et al. 2000. Int. J. Cancer89, 361.
Inohara, H. 1999. Cancer85, 2475.
Nakamura, M., et al. 1999. Int. J. Oncol.15, 143.
Idikio, H., et al. 1998. Int. J. Oncol.12, 1287.
Ochieng, J., et al. 1998. Biochim. Biophys. Acta.1379 97.
Castronovo, V., et al. 1996. J. Pathol.179, 43.
Liu, F.T., et al. 1996. Biochemistry35 6073.
Schoeppner, H. L., et al. 1995. Cancer75, 2818.
Massa, S.M., et al. 1993. Biochemistry32, 260.
Oda, Y., et al. 1991. Gene99, 279.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)